GSK: two days’ data do not a trend make

Share this article:
Financial analysts, known for their penchant to wield prescribing data, may have jumped the gun recently.

Deutsche Bank analysts wrote in an investor note that new prescriptions for GlaxoSmithKline diabetes drug Avandia fell to about zero from 10% during the two days from May 22 to May 23. “Two days of data is not enough to reach sensible conclusions on the trend for Avandia new prescriptions,” GSK later told Bloomberg.

ImpactRx, which supplied the data on which the analysts based their May 23 note, added, “We believe insufficient time has elapsed…and it’s premature to conclude any dramatic or lasting changes in physician prescribing behavior at this point.” Either way, scripts have dropped since a May 21 article reported that Avandia users were 43% more likely to have a heart attack.

ImpactRx has done business with GSK and Deutsche Bank, but president and CEO Richard Altus said GSK had not pressured him to issue the caveat.

In early June, IMS Health released data showing Avandia NRx declined 16% in the first week after the journal article. GSK’s SVP for pharmaceuticals and vaccines was quoted as saying figures showed a 15% to 20% drop in Avandia prescriptions since the paper appeared.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.